Why the study?
To investigate the mechanism by which Shenbing decoction III alleviates proteinuria in chronic kidney disease based on network pharmacology.
Network pharmacology analysis suggests Shenbing decoction III may treat CKD proteinuria via fluid shear stress and atherosclerosis-related pathways.
Hypothesis-generating for Ⅲ in CKD proteinuria; clinical trials needed before any therapeutic consideration.
OBJECTIVE: Ⅲ alleviates proteinuria in chronic kidney disease (CKD) based on network pharmacology. METHODS: Ⅲ and their potential targets, along with the oral bioavailability and drug-like properties of each component were searched in the TCMSP database. The proteinuria-related targets were searched in the GeneCards database. The active component-target network was constructed using Cytoscape software, and the acquired information of the targets from ClueGO was used for enrichment analysis of the gene pathways. RESULTS: Ⅲ. These active components acted on 126 targets, among which 69 were related to proteinuria. Enrichment analysis revealed fluid shear stress- and atherosclerosisrelated pathways as the highly significant pathways in proteinuria associated with CKD. CONCLUSIONS: Ⅲ in the treatment of proteinuria in CKD.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: